Boundless Bio, Inc. (BOLD) Revenue, Earnings & Financial Statements
$2.41NASDAQ: BOLDMarket Cap $56.90M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Boundless Bio, Inc. most recently reported annual revenue of $0, a net loss of $58.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Boundless Bio, Inc.: net profit was positive in 0 of 8 reported years; the most recent year shows a net loss of $58.0M.
Income Statement — 8 Years (USD millions)
Metric
2016
2017
2018
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$60.0M
$93.0M
$134.0M
$25.0M
$46.0M
$55.0M
$73.0M
$64.0M
Operating Profit
−$60.0M
−$93.0M
−$134.0M
−$25.0M
−$46.0M
−$55.0M
−$73.0M
−$64.0M
Other Income
$0
$1.0M
$6.0M
$0
$1.0M
$5.0M
$8.0M
$5.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$2.0M
$4.0M
$7.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Profit Before Tax
−$60.0M
−$92.0M
−$129.0M
−$25.0M
−$46.0M
−$49.0M
−$65.0M
−$58.0M
Tax rate (%)
-0.6%
2.4%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$60.0M
−$90.0M
−$129.0M
−$25.0M
−$46.0M
−$49.0M
−$65.0M
−$58.0M
EPS
−$5.59
−$3.40
−$2.93
−$1.13
−$2.06
−$2.22
−$3.85
−$2.60
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$14.0M
$17.0M
$19.0M
$19.0M
$18.0M
$17.0M
$17.0M
$15.0M
$14.0M
$14.0M
$24.0M
$6.0M
Operating Profit
−$14.0M
−$17.0M
−$19.0M
−$19.0M
−$18.0M
−$17.0M
−$17.0M
−$15.0M
−$14.0M
−$14.0M
−$24.0M
−$6.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$12.0M
−$15.0M
−$17.0M
−$17.0M
−$16.0M
−$16.0M
−$16.0M
−$14.0M
−$13.0M
−$14.0M
−$24.0M
−$5.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$12.0M
−$15.0M
−$17.0M
−$17.0M
−$16.0M
−$16.0M
−$16.0M
−$14.0M
−$13.0M
−$14.0M
−$24.0M
−$5.0M
EPS
−$0.55
−$0.69
−$0.77
−$0.74
−$0.84
−$0.71
−$0.70
−$0.62
−$0.58
−$0.60
−$1.06
−$0.23
Over the 8 years reported for Boundless Bio, Inc., borrowings increased from $3.0M in 2016 to $49.0M in 2025, cash stood at $18.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 8.46 times.
Balance Sheet — 8 Years (USD millions)
Metric
2016
2017
2018
2021
2022
2023
2024
2025
Total Assets
$142.0M
$179.0M
$473.0M
$114.0M
$77.0M
$130.0M
$206.0M
$157.0M
Current Assets
$108.0M
$137.0M
$420.0M
$75.0M
$68.0M
$124.0M
$154.0M
$110.0M
Cash
$36.0M
$39.0M
$144.0M
$34.0M
$11.0M
$24.0M
$27.0M
$18.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
$19.0M
$24.0M
$32.0M
$3.0M
$8.0M
$5.0M
$51.0M
$47.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$69.0M
$95.0M
$270.0M
$74.0M
$56.0M
$98.0M
$126.0M
$90.0M
Other Assets
$4.0M
$4.0M
$4.0M
$0
$0
$0
$0
$0
Total Liabilities
$23.0M
$22.0M
$30.0M
$152.0M
$159.0M
$257.0M
$56.0M
$58.0M
Current Liabilities
$13.0M
$18.0M
$24.0M
$4.0M
$8.0M
$9.0M
$8.0M
$13.0M
Borrowings
$3.0M
$7.0M
$7.0M
$0
$5.0M
$2.0M
$48.0M
$49.0M
Other Liabilities
$20.0M
$15.0M
$23.0M
$152.0M
$153.0M
$255.0M
$8.0M
$9.0M
Equity
$300.0M
$300.0M
$300.0M
$0
$0
$0
$0
$0
Reserves
$119.0M
$157.0M
$443.0M
−$38.0M
−$82.0M
−$127.0M
$151.0M
$99.0M
For Boundless Bio, Inc., operating cash flow was positive in 0 of 8 reported years; free cash flow in the latest year was negative at $47.0M; free cash flow was positive in 0 of 8 years.
Cash Flow Statement — 8 Years (USD millions)
Metric
2016
2017
2018
2021
2022
2023
2024
2025
Operating Cash Flow
−$49.0M
−$85.0M
−$108.0M
−$23.0M
−$40.0M
−$47.0M
−$61.0M
−$47.0M
Investing Cash Flow
−$79.0M
−$41.0M
−$197.0M
−$61.0M
$15.0M
−$39.0M
−$29.0M
$37.0M
Financing Cash Flow
$39.0M
$82.0M
$254.0M
$0
$0
−$2.0M
−$3.0M
$0
Net Cash Flow
−$36.0M
$3.0M
$105.0M
$23.0M
−$23.0M
$13.0M
$3.0M
−$9.0M
Free Cash Flow
−$66.0M
−$92.0M
−$120.0M
−$25.0M
−$41.0M
−$47.0M
−$63.0M
−$47.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-0.10
EV / EBITDA
-0.45
FCF Yield
-97.25%
Quick Ratio
33.97
Interest Coverage
—
Return 1Y
104.24%
Return 3Y
—
Return 5Y
—
Boundless Bio, Inc. (BOLD) financials — frequently asked questions
What is Boundless Bio, Inc.'s annual revenue?
Boundless Bio, Inc. (BOLD) reported annual revenue of $0 in its most recent fiscal year.
What is Boundless Bio, Inc.'s net profit?
Boundless Bio, Inc. (BOLD) reported a net loss of $58.0M in its most recent fiscal year.
What is BOLD EV/EBITDA?
Boundless Bio, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.45. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks